RxDoctor Payments Data

Ankush Gulati, MD

Nephrology · Lehigh Acres, FLNPI 1265445654

Payments from drug & device makers

$64,106in general payments, 2019–2025

Across 349 payments — averaging $183.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$30K
  • Vertex$23K
  • Akebia Therapeutics Inc$5K
  • Calliditas Therapeutics US Inc.$623
  • Travere Therapeutics, Inc.$554
  • OPKO Pharmaceuticals, LLC$552
  • plus $4K from 20 others

What the payments were for

  • Speaking & faculty fees$32,19079%
  • Travel & lodging$3711%
  • Food & beverage$8,30320%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,106 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$661,879
Medicare patients
1,269
Services billed
5,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol1,028$1,258,431
KerendiaFinerenone413$583,173
OzempicSemaglutide213$283,845
JardianceEmpagliflozin179$242,162
VelphoroSucroferric Oxyhydroxide40$113,376
XphozahTenapanor Hcl26$96,721
MounjaroTirzepatide58$69,524
LokelmaSodium Zirconium Cyclosilicate19$33,999
RayaldeeCalcifediol21$33,020
DapagliflozinDapagliflozin Propanediol35$20,313
Torsemide841$18,203
Calcitriol503$13,534
Clonidine48$4,333
Sevelamer Carbonate15$2,685
Febuxostat21$2,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$29,893$1,292,4301,047 claims
BayerKerendia$390$583,173413 claims
Novo NordiskOzempic$500$283,845213 claims
Boehringer IngelheimJardiance$269$242,162179 claims
Fresenius USA Marketing, Inc.Velphoro$108$113,37640 claims
Lilly USA, LLCMounjaro$88$69,52458 claims
OPKO Pharmaceuticals, LLCRayaldee$552$33,02021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Lehigh Acres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →